Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Apellis Pharmaceuticals Inc. will escape an investor lawsuit alleging it concealed safety risks connected to its ...

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of ...

In a report released on March 21, Umer Raffat from Evercore ISI maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report).

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million ...

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

Apellis Q4 loss was $0.29 per share, beating estimates of $0.37; revenue grew 45.2% to $212.5M, surpassing the $198.35M consensus. Syfovre sales hit $167.8M in Q4 and $611.9M for 2024, with over ...